Oppenheimer Bullish on Life Tech's Ion Proton Instrument as Anticipated Launch Nears | GenomeWeb

NEW YORK (GenomeWeb News) – Anticipating the expected launch of the Life Technologies' Ion Proton benchtop sequencer, Oppenheimer analyst David Ferreiro today estimated 140 placements of the system in 2012 translating to $35.3 million in revenues.

He added that he estimates 200 placements of Ion Proton in 2013 and 300 placements in 2014, which would result in revenues of $75 million and $150.7 million, respectively.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

Widespread genome sequencing might not be justified just yet, USA Today reports.